Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Bullish +75

Amgen adds $300M in Puerto Rico, nearing $1B total

🏭 Amgen announced a new $300 million investment to expand its biologics manufacturing facility in Juncos, Puerto Rico.

🌍 The Juncos site was established in 1992 and currently produces medicines distributed to more than 60 countries.

💵 This new commitment brings the total planned investment on the island to nearly $1 billion over the past year.

🇺🇸 Amgen's broader U.S. manufacturing pledges now total nearly $2 billion with this latest addition.

📈 The expansion aims to increase production capacity, create advanced manufacturing roles, and generate hundreds of construction jobs.

⚙️ The investment will support next-generation manufacturing technologies and strengthen the company's domestic supply chain.

💬 CEO Robert Bradway stated the expansion reflects Amgen's continued commitment to American manufacturing and supporting the long-term strength of the supply chain.

🤝 The $300 million investment follows a previous $650 million commitment for the same Puerto Rico site.

📍 Amgen also has significant investments in Ohio ($900 million), California ($600 million for a science and innovation center), and North Carolina (more than $1.5 billion).

🏛️ Local officials, including Governor Jenniffer González, praised the investment as a testament to Puerto Rico's excellence and skilled workforce in biopharmaceuticals.

🔍 The move comes amid industry-wide efforts by global drugmakers to increase U.S. manufacturing capacity in response to tariff policy proposals.

💊 Expanding domestic production is expected to ensure patients have continued access to essential medicines.

🏗️ Secretary Sebastián Negrón highlighted that the total nearly $1 billion investment represents strong confidence in Puerto Rico's capabilities for producing life-saving medicines.

Bullish Signals
  • Amgen announced an additional $300 million investment to expand its biologics manufacturing facility in Juncos, Puerto Rico.
  • The new commitment brings the company's total planned investment on the island to nearly $1 billion over the past year.
  • This expansion will significantly increase production capacity and generate hundreds of construction jobs.
  • Amgen stated the investment supports advanced manufacturing roles and strengthens its domestic supply chain.
  • With this new facility, Amgen will continue to produce medicines distributed to more than 60 countries worldwide.
  • The $300 million commitment represents nearly $1 billion in confidence in Puerto Rico's workforce, capabilities, and infrastructure for biomanufacturing.
Risk Factors
  • Amgen faces significant regulatory and operational risks as it navigates the complex tariff policy proposals affecting pharmaceutical imports, particularly with its new $300M investment in Puerto Rico.
  • The company's heavy capital expenditure strategy, nearing $1 billion for Puerto Rico and nearly $2 billion total for U.S. manufacturing pledges, raises concerns about near-term profitability and balance sheet strain.
Full Analysis
Amgen has announced an additional $300 million investment to expand its biologics manufacturing facility in Juncos, Puerto Rico. This site, established in 1992, is currently one of the largest biologics manufacturing facilities in the world and supplies medicines to over 60 countries. With this new commitment, Amgen's total planned investment on the island has reached nearly $1 billion over the past year, while its broader U.S. manufacturing pledges are approaching $2 billion. The expansion is designed to increase production capacity, create hundreds of construction jobs, support advanced manufacturing roles, and enhance workforce development initiatives. Robert A. Bradway, Amgen's chairman and CEO, stated that this growth reflects the company's long-standing commitment to American manufacturing and aims to ensure patient access to necessary medicines while strengthening the domestic supply chain against tariff pressures. This investment follows a previous $650 million announcement for the same Juncos site. It is part of a larger trend among global pharmaceutical companies to increase U.S. manufacturing capacity, including significant recent pledges for Ohio ($900 million), California ($600 million), and North Carolina (over $1.5 billion). Local officials, including Governor Jenniffer González, emphasized that this capital injection reinforces Puerto Rico's reputation for excellence in the biopharmaceutical sector and validates the region's skilled workforce and infrastructure capabilities.